Loading stock data…
Equillium (EQ)
$2.41+0.20 (+9.05%)
Market ClosedLast close Sep 8
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Equillium, Inc. in the Healthcare sector is trading at $2.41 with a market capitalization of $172M. Wall Street consensus targets $8.56 (9 analysts), implying a +255.0% move over the next 12 months. The stock is currently 32% below its 52-week high of $3.54, remaining 21.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +255.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.61M↓ | -$3.96M↑ | -$4.58M↑ | -$6.23M↑ | -$8.87M |
| Net Income | -$5.31M↓ | -$3.77M↑ | -$4.23M↑ | -$5.74M↑ | -$8.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$171.98M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.03%
Volume
Today's trading volume
597,780
Recent News
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504
Equillium, Inc. (NASDAQ:EQ), with a year-to-date gain of 89.68% and upside potential of 121.10%, secures a spot on our list of hot biotech stocks under $5 to buy. Two analyst updates landed on the same day, both pointing to growing conviction around the company’s lead asset. On May 28, 2026, Leerink upgraded Equillium, Inc. (NASDAQ:EQ) […]
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124, a microRNA implicated in inflammatory disease biology. The presentation, titled “Insights to
Here’s What Roth Capital Thinks of Equillium (EQ) Stock
Equillium, Inc. (NASDAQ:EQ) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 13, Roth Capital analyst Adam Walsh initiated coverage of Equillium, Inc. (NASDAQ:EQ), assigning a Buy rating and a price target of $12. The firm’s assigned price target suggests a compelling 458% upside from the current levels. The […]
Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start
Executives from Equillium (NASDAQ:EQ) outlined the scientific rationale and near-term development plans for its lead program, EQ504, during a recent fireside chat focused on immunology and inflammatory bowel disease (IBD). Positioning EQ504 in ulcerative colitis Company representatives described ul